Bertrand Cayrol
Keine laufenden Positionen mehr
Karriereverlauf von Bertrand Cayrol
Ehemalige bekannte Positionen von Bertrand Cayrol
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Société Innovatech du Grand Montréal | Corporate Officer/Principal | 01.01.1992 | 31.12.1996 |
Cytheris SA
 Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Direktor/Vorstandsmitglied | 15.12.2009 | - |
Transfer Technologies Commercialisation Capital
 Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Private Equity Investor | 01.01.1997 | - |
Ausbildung von Bertrand Cayrol
| Ecole Nationale Superieure de Chimie de Toulouse | Undergraduate Degree |
| McGill University | Doctorate Degree |
Statistik
International
| Kanada | 4 |
| Frankreich | 3 |
Operativ
| Private Equity Investor | 1 |
| Corporate Officer/Principal | 1 |
| Director/Board Member | 1 |
Sektoral
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |
| Société Innovatech du Grand Montréal | |
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Health Technology |
- Börse
- Insiders
- Bertrand Cayrol
- Erfahrung
